While GLP-1 and its analogues are important pharmaceuticalagents in the treatment of type 2 diabetes and obesity, their susceptibilityto aggregate into amyloid fibrils poses a significant safety issue.Many factors may contribute to the aggregation propensity, includingpH. The gene discussed is GLP1R; the disease is obesity disorder.